Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)

Virginia Commonwealth University (VCU)

Status and phase: Terminated; Early Phase 1

Conditions: Chronic Obstructive Pulmonary Disease

Treatments: Drug: MitoQ; Other: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT05605548

HM20021976

905812 (Other Grant/Funding Number)

Details and patient eligibility

About

Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in improving cardiovascular outcomes in similar populations. Thus the purpose of this study is to test if MitoQ can improve cardiovascular health in COPD.

Full description

In this study, a mitochondria-specific antioxidant will be compared to a placebo. Participants will be assigned randomly to receive either the antioxidant or the placebo for 6 weeks. A comprehensive assessment of cardiovascular health will be conducted before and after the administration of the supplement.

Enrollment: 4 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinically diagnosed of COPD
• Global Initiative for obstructive lung disease (GOLD) Stages II to IV

Exclusion criteria

• Forced Expiratory Volume in 1 second/ Functional Vital Capacity (FEV1/FVC) >0.7
• Heart Disease
• Diabetes
• Vasoactive medications
• Uncontrolled high blood pressure
• Fluid in lungs
• Sleep apnea
• Raynaud's Phenomenon
• Gangrene of the digits
• History of coagulation
• Pregnant women
• Children

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

4 participants in 2 patient groups, including a placebo group

MitoQ

Experimental group

Description:

Participants will take 1 pill each day for 6 weeks

Treatment:

Drug: MitoQ

Placebo

Placebo Comparator group

Description:

Participants will take 1 pill each day for 6 weeks

Treatment:

Other: Placebo